GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (FRA:44R3) » Definitions » EV-to-FCF

Phio Pharmaceuticals (FRA:44R3) EV-to-FCF : 0.53 (As of Jun. 18, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Phio Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Phio Pharmaceuticals's Enterprise Value is €-4.90 Mil. Phio Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-9.30 Mil. Therefore, Phio Pharmaceuticals's EV-to-FCF for today is 0.53.

The historical rank and industry rank for Phio Pharmaceuticals's EV-to-FCF or its related term are showing as below:

FRA:44R3' s EV-to-FCF Range Over the Past 10 Years
Min: -9.6   Med: 0.14   Max: 1.11
Current: 0.52

During the past 13 years, the highest EV-to-FCF of Phio Pharmaceuticals was 1.11. The lowest was -9.60. And the median was 0.14.

FRA:44R3's EV-to-FCF is ranked better than
74.74% of 384 companies
in the Biotechnology industry
Industry Median: 7.885 vs FRA:44R3: 0.52

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-18), Phio Pharmaceuticals's stock price is €5.8116. Phio Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-2.425. Therefore, Phio Pharmaceuticals's PE Ratio for today is At Loss.


Phio Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Phio Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals EV-to-FCF Chart

Phio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.22 0.86 0.53 0.52

Phio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.47 0.44 0.52 0.33

Competitive Comparison of Phio Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Phio Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phio Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's EV-to-FCF falls into.



Phio Pharmaceuticals EV-to-FCF Calculation

Phio Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-4.898/-9.298
=0.53

Phio Pharmaceuticals's current Enterprise Value is €-4.90 Mil.
Phio Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Phio Pharmaceuticals  (FRA:44R3) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Phio Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.8116/-2.425
=At Loss

Phio Pharmaceuticals's share price for today is €5.8116.
Phio Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.425.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Phio Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Phio Pharmaceuticals (FRA:44R3) Business Description

Traded in Other Exchanges
Address
257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.

Phio Pharmaceuticals (FRA:44R3) Headlines

No Headlines